MicroRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Feng, Yougang ^a   Kang, Yongming ^a   He, Yue ^a   Liu, Jun ^a   Liang, Bo ^a   Yang, Ping ^a   Yu, Zhou ^a  

^a SUINING CENTRAL HOSPITAL   (China)

Author keywords

Bladder cancer; Circulation miRNA; miR 99a

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; MICRORNA; MICRORNA 99A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLADDER CARCINOGENESIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PLASMA; REAL TIME POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; URINARY BLADDER NEOPLASMS;

EID: 84902758320     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-50     Document Type: Article

References (29)

1. Molecular pathogenesis of bladder cancer. Knowles MA, Int J Clin Oncol 2008 13 287 297 10.1007/s10147-008-0812-0 18704628
2. Identification of p53 gene mutations in bladder cancers and urine samples. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Science 1991 252 706 709 10.1126/science.2024123 2024123 (Pubitemid 21916998)
3. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA, Oncogene 2005 24 5218 5225 10.1038/sj.onc.1208705 15897885 (Pubitemid 41192438)
4. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF, Cancer Res 2001 61 8659 8663 11751381 (Pubitemid 34013873)
5. MicroRNA gene expression deregulation in human breast cancer. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM, Cancer Res 2005 65 7065 7070 10.1158/0008-5472.CAN-05-1783 16103053 (Pubitemid 41161233)
6. Expression profiling identifies microRNA signature in pancreatic cancer. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD, Int J Cancer 2007 120 1046 1054 17149698 (Pubitemid 46214304)
7. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC, Cancer Cell 2006 9 189 198 10.1016/j.ccr.2006.01.025 16530703 (Pubitemid 43357945)
8. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K, Oncogene 2006 25 2537 2545 10.1038/sj.onc.1209283 16331254
9. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J, Cancer Res 2010 70 6015 6025 10.1158/0008-5472.CAN-09-4531 20610624
10. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, Yang K, He X, Chen S, J Hepatol 2010 53 98 107 10.1016/j.jhep.2010.02.021 20447717
11. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Kosaka N, Iguchi H, Ochiya T, Cancer Sci 2010 101 2087 2092 10.1111/j.1349-7006.2010.01650.x 20624164
12. MicroRNAs in body fluids the mix of hormones and biomarkers. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA, Nat Rev Clin Oncol 2011 8 467 477 10.1038/nrclinonc.2011.76 21647195
13. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Taylor DD, Gercel-Taylor C, Gynecol Oncol 2008 110 13 21 10.1016/j.ygyno.2008.04.033 18589210 (Pubitemid 351853251)
14. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, Li Z, Tang A, Li X, Ye J, Guan Z, Gui Y, Cai Z, PLoS One 2011 6 18286 10.1371/journal.pone.0018286 21464941
15. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC, Cancer Res 2009 69 8472 10.1158/0008-5472.CAN-09-0744 19843843
16. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y, Sun N, Xu X, Shao K, He J, Med Oncol 2013 30 411 23292834
17. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, Zheng L, Xue Z, Xia W, Zhang B, Ding T, Cao Y, Tian Z, Shi Q, He X, BMC Cancer 2012 12 546 10.1186/1471-2407-12-546 23173671
18. Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. Yan B, Fu Q, Lai L, Tao X, Fei Y, Shen J, Chen Z, Wang Q, Mol Med Rep 2012 6 675 681 22751686
19. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF, Cancer Res 2009 69 4851 4860 10.1158/0008-5472.CAN-08-4043 19487295
20. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Kawahara K, Nishiyama K, Seki N, Nakagawa M, Cancer Sci 2011 102 522 529 10.1111/j.1349-7006.2010.01816.x 21166959
21. Expression of microRNAs in the urine of patients with bladder cancer. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF, Clin Genitourin Cancer 2012 10 106 113 10.1016/j.clgc.2012.01.001 22386240
22. Circulating microRNAs as potential new biomarkers for prostate cancer. Sita-Lumsden A, Dart DA, Waxman J, Bevan CL, Br J Cancer 2013 108 1925 1930 10.1038/bjc.2013.192 23632485
23. Detection of elevated levels of tumour associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL, Br J Haematol 2008 141 672 675 10.1111/j.1365-2141.2008.07077.x 18318758 (Pubitemid 351667616)
24. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S, PLoS One 2010 5 13735 10.1371/journal.pone.0013735 21060830
25. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H, J Clin Oncol 2010 28 1721 1726 10.1200/JCO.2009.24.9342 20194856
26. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J, Urology 2011 77 1265
27. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC, Ellinger J, PLoS One 2011 6 25787 10.1371/journal.pone.0025787 21984948
28. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC, Ellinger J, World J Urol 2012 doi:10.1007/s00345-012-1010-2
29. Plasma microRNA profiles for bladder cancer detection. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang JD, Jackson D, Dinney CP, Urol Oncol 2013 31 1701 1708 10.1016/j.urolonc.2012.06.010 22863868